Shenzhen TargetRx Co., Ltd.

Houston, Texas

OncologyPhase II

What changed

Phase II trial registered: Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

5w agoTrial registeredJun 8, 2026Source filing (opens the source filing in a new tab)

Momentum

89no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,008 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE2 registered
Aug 27, 2026
Phase II Clinical Trial, Blinatumomab, Olverembatinib, Lymphoblastic Leukemia, Philadelphia Chromosome Positive · NOT_YET_RECRUITING · sponsor: M.D. Anderson Cancer Center · Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
ClinicalTrials.gov · NCT07178912 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jul 2, 2024
Chronic Myelogenous Leukemia · RECRUITING · sponsor: Shenzhen TargetRx Co., Ltd. · TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
ClinicalTrials.gov · NCT06088888 (opens the source filing in a new tab)
Trial
PHASE2 registered
Jan 31, 2024
Chronic Myeloid Leukemia · RECRUITING · sponsor: M.D. Anderson Cancer Center · Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
ClinicalTrials.gov · NCT06236724 (opens the source filing in a new tab)
Trial
PHASE2 registered
Feb 19, 2016
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia · ACTIVE_NOT_RECRUITING · sponsor: M.D. Anderson Cancer Center · Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
ClinicalTrials.gov · NCT02689440 (opens the source filing in a new tab)
Trial
PHASE2 registered
Jan 17, 2013
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive · RECRUITING · sponsor: M.D. Anderson Cancer Center · Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
ClinicalTrials.gov · NCT01746836 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 78%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
5w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
5w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
2mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
4mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
4mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
4mo agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial now recruiting: TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Feb 2025Trial recruitingSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

PHASE2 registered

PHASE1 registered

PHASE2 registered

PHASE2 registered

PHASE2 registered